Are Remnant-Like Particles Independent Predictors of Coronary Heart Disease Incidence?
The Honolulu Heart Study

Claudia Imke, Beatriz L. Rodriguez, John S. Grove, Judith R. McNamara, Carol Waslien, Alan R. Katz, Bradley Willcox, Katsuhiko Yano, J. David Curb

Background—Remnant-like particles have been proposed as a new risk factor for coronary heart disease (CHD). This is the first long-term prospective investigation of the relationship between remnant-like particles and a cardiovascular disease outcome in healthy men.

Methods and Results—A cohort of 1156 Japanese-American men aged 60 to 82 from the Honolulu Heart Program was followed for 17 years. During that period 164 incident cases of CHD were identified. In multivariate Cox regression analyses, baseline remnant-like particle cholesterol (RLP-C) and triglyceride (RLP-TG) levels were significantly related to CHD incidence independently of nonlipid cardiovascular risk factors and of total cholesterol or high-density and low-density lipoprotein cholesterol levels. Total triglyceride levels were an independent predictor of CHD incidence. However, in models including RLP and triglyceride level simultaneously, neither variable was significant when adjusted for the other. This finding can be attributed to the strong correlation between RLP-C and RLP-TG levels and total triglycerides. When individuals with normal triglyceride levels (n=894) were separated from those with elevated triglycerides (n=260), the association between RLPs and CHD relative risk was only significant for the group with elevated triglyceride levels.

Conclusions—RLP levels predicted CHD incidence independently of nonlipid risk factors and of total cholesterol or high-density and low-density lipoprotein cholesterol levels. However, RLP levels did not provide additional information about CHD incidence over and above total triglyceride levels. Therefore, this study does not support the need for testing of remnants in men if measures of fasting triglycerides are available. (Arterioscler Thromb Vasc Biol. 2005;25:0-0.)

Key Words: coronary heart disease ■ lipoproteins ■ triglycerides ■ remnant ■ Asian Americans
Kugiyama et al found that higher levels of remnants in fasting serum were an independent predictor of developing coronary events in 135 patients with coronary artery disease. RLP cholesterol (RLP-C) in fasting plasma was associated with prevalent CVD in 1567 white women from the Framingham Heart Study after adjustment for other major cardiovascular risk factors. In addition, plasma concentration of RLP-C was associated with carotid artery intima-media thickness, especially for RLP-C levels 3 hours after receiving a rich fat meal.

Because the Honolulu Heart Program (HHP) is a large prospective study of CHD with one of the longest follow-up periods in the world and its participants have a wider range of baseline triglyceride levels compared with other American white populations, the HHP is an ideal population for defining the independent relationship between RLP and CHD. The objectives of this study were the following: (1) to examine the association of fasting RLP-C and RLP-TG levels with 17-year incidence of CHD in a sample of elderly Japanese-American men after adjustment for nonlipid cardiovascular risk factors; and (2) to evaluate how this relationship is affected by other lipids and lipoproteins such as total cholesterol, LDL and high-density lipoprotein (HDL) cholesterol or total triglycerides.

**Methods**

**Study Population**

The Honolulu Heart Program (HHP) cohort of Japanese-American men aged 45 to 68 and living on Oahu, Hawaii, was identified and recruited from selective service records. A total of 8006 subjects completed a baseline examination between 1965 and 1968. A 30% random sample of the participants was selected for the Cooperative Lipoprotein Phenotyping study from 1970 to 1972. Survivors of this cohort were subsequently examined from 1980 to 1982. Data and samples from this latter examination, Lipoprotein Examination 3, were used as the baseline data for the present analysis.

Fasting plasma samples were obtained for lipid determinations. At that time the study participants were aged 60 to 82. Of the 1379 men, 223 had prevalent CHD or stroke or were taking lipid-lowering medication and, therefore, were excluded from these analyses, leaving 1156 subjects who constituted the study population.

**Data Collection**

Follow-up for incident CHD was conducted through 1997 using standardized clinical criteria. Definite CHD included nonfatal myocardial infarction confirmed by electrocardiogram and/or enzyme changes. It also included any angina diagnosis that went on to myocardial infarction confirmed by electrocardiogram and/or enzyme changes. It also included any angina diagnosis that went on to myocardial infarction confirmed by electrocardiogram and/or enzyme changes. It also included any angina diagnosis that went on to myocardial infarction confirmed by electrocardiogram and/or enzyme changes. It also included any angina diagnosis that went on to myocardial infarction confirmed by electrocardiogram and/or enzyme changes.

**Statistical Analysis**

Multivariate Cox proportional hazard models were used to estimate the 17-year relative risk of CHD for RLP-C and RLP-TG levels associated with 1 increase of 2 SD. Adjustments were made for age, BMI, smoking, alcohol intake, physical activity, systolic blood pressure, fasting glucose, history of diabetes and intake of antihypertensive medication. Total cholesterol, HDL and LDL cholesterol, or total triglycerides were included as additional covariates in some of the models. These analyses were repeated using log-transformed RLP variables.

Fit of the Cox model was evaluated by permitting the effect of RLP-C and RLP-TG levels to vary with time and by entering squared terms for RLP-variables into the models. All reported probability values are based on 2-sided tests of significance.

**Results**

Among the 1156 observations included in the analyses, 164 incident cases of CHD were identified. Table 1 displays descriptive statistics for RLP-C and RLP-TG levels and all covariates that were used in the models.

The effect of RLP-C and RLP-TG levels on CHD relative risk after adjustment for potential confounding variables are presented in Table 2. Each model included the basic set of nonlipid variables: age, BMI, smoking, alcohol intake, physical activity, systolic blood pressure, fasting glucose, history of diabetes and intake of antihypertensive medication, and 1 additional set of covariates. Adding squared terms of the RLP variables did not improve the fit of the models (results not shown). CHD relative
risk estimates for RLP levels are reported for an increase of 2 SD (23.85 mg/dL for RLP-C and 112.81 mg/dL for RLP-TG).

Models that included RLP as the only lipid variable showed a significant effect for RLP-C and RLP-TG levels on CHD relative risk ($P=0.0022$ and $P=0.0045$, respectively).

For the models that included total cholesterol or HDL and LDL cholesterol as additional covariates, RLP-C and RLP-TG were the only lipid variables that were significant.

Fasting triglyceride level was an independent predictor of CHD relative risk after adjustment for age, BMI, smoking, alcohol intake, physical activity, systolic blood pressure, fasting glucose, history of diabetes, intake of antihypertensive medication, and LDL and HDL cholesterol (relative risk ($P=0.0022$ and $P=0.0045$, respectively)).

When the previous analyses were repeated using log-transformed RLP, the results were similar, but the probability values were somewhat larger for the first 3 models; RLP-C and RLP-TG were only of borderline significance in model 3 ($P=0.066$ and 0.082, respectively). For model 4, the probability values were smaller when both RLPs and triglycerides were log-transformed ($P=0.21$ for (log)RLP-C and $P=0.43$ for (log)RLP-TG). The probability values for (log)RLP-C were generally smaller than the probability values for (log)RLP-TG in the corresponding models.

The previous analysis (Model 1) was also conducted separately for people with normal triglyceride levels ($n=894$, including 115 CHD cases) and those with elevated triglycerides ($n=260$, including 49 CHD cases). After adjustment for age, BMI, smoking, alcohol intake, physical activity, systolic blood pressure, fasting glucose, history of diabetes and intake of antihypertensive medication, only the group with elevated triglycerides showed a significant association between RLP-C and RLP-TG levels and CHD relative risk ($P=0.026$ and $P=0.014$, respectively). However, regression-coefficient estimates (log relative risk per mg/dL) for RLP were similar for both groups: for RLP-C $0.0094$ in the group with normal triglycerides and 0.011 in the group with elevated triglycerides; for RLP-TG 0.0023 in the group with normal triglycerides and 0.0028 in the group with elevated triglycerides. Standard errors for the RLP-C and RLP-TG variables were much higher in the group with normal triglyceride levels (0.037 and 0.013, respectively) than in the group with elevated triglycerides (0.0051 and 0.0011, respectively). A test for an interaction effect between RLP and triglyceride level was not significant. Similar to the result using the total sample, in models including an RLP variable and triglyceride level simultaneously, neither variable was significant when adjusted for the other in the group with elevated triglycerides.

After including the cross-product of the RLP variables with time or log-transformed time variables in the models, no evidence was found for time dependency of the relationship between RLPs and CHD relative risk.

Because of the unusual results when both RLP and triglyceride levels were included in the same model, the correlations

### Table 1. Descriptive Statistics for RLP Levels and Covariates

<table>
<thead>
<tr>
<th>Variable</th>
<th>Mean (SD)</th>
</tr>
</thead>
<tbody>
<tr>
<td>RLP-C, mg/dL</td>
<td>10.46 [6.9]</td>
</tr>
<tr>
<td>RLP-TG, mg/dL</td>
<td>35.55 [18.6]</td>
</tr>
<tr>
<td>Age, years</td>
<td>67.70</td>
</tr>
<tr>
<td>BMI, kg/m²</td>
<td>23.55</td>
</tr>
<tr>
<td>Smoking, cigarettes/day</td>
<td>3.93</td>
</tr>
<tr>
<td>Alcohol intake, oz/week</td>
<td>3.41</td>
</tr>
<tr>
<td>Physical activity index</td>
<td>30.81</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>138.90</td>
</tr>
<tr>
<td>Fasting glucose, mg/dL</td>
<td>113.40</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>209.62</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>47.82</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>135.71</td>
</tr>
<tr>
<td>Total triglycerides, mg/dL</td>
<td>164.23</td>
</tr>
</tbody>
</table>

*Measures are skewed to the right; therefore, medians are provided in brackets.

### Table 2. Age-Adjusted Correlations of Log-Transformed RLP-C and RLP-TG With CHD Risk Factors

<table>
<thead>
<tr>
<th>Variable</th>
<th>(Log)RLP-C, mg/dL</th>
<th>(Log)RLP-TG, mg/dL</th>
</tr>
</thead>
<tbody>
<tr>
<td>BMI, kg/m²</td>
<td>0.22†</td>
<td>0.27†</td>
</tr>
<tr>
<td>Smoking, cigarettes/day</td>
<td>−0.048</td>
<td>−0.044</td>
</tr>
<tr>
<td>Alcohol intake, oz/week</td>
<td>0.079*</td>
<td>0.13†</td>
</tr>
<tr>
<td>Physical activity index</td>
<td>−0.090*</td>
<td>−0.093*</td>
</tr>
<tr>
<td>Systolic blood pressure, mm Hg</td>
<td>0.12†</td>
<td>0.16†</td>
</tr>
<tr>
<td>Antihypertensive drugs, yes/no</td>
<td>0.16†</td>
<td>0.19†</td>
</tr>
<tr>
<td>Fasting glucose, mg/dL</td>
<td>0.096*</td>
<td>0.15†</td>
</tr>
<tr>
<td>History of diabetes, yes/no</td>
<td>−0.0073</td>
<td>0.024</td>
</tr>
<tr>
<td>Total cholesterol, mg/dL</td>
<td>0.37†</td>
<td>0.19†</td>
</tr>
<tr>
<td>HDL cholesterol, mg/dL</td>
<td>−0.43†</td>
<td>−0.48†</td>
</tr>
<tr>
<td>LDL cholesterol, mg/dL</td>
<td>−0.022</td>
<td>−0.21†</td>
</tr>
<tr>
<td>(Log)total triglycerides, mg/dL</td>
<td>0.88†</td>
<td>0.93†</td>
</tr>
</tbody>
</table>

*P<0.01; †P<0.0001.
between the 2 log-transformed RLP variables and other CHD risk factors were computed. As shown in Table 2, (log)triglyceride level was strongly correlated with (log)RLP-C and (log)RLP-TG level ($r=0.88$ and $r=0.93$, respectively).

In addition, inclusion of people taking lipid-lowering medication ($n=20$) did not significantly affect the results (results not shown).

**Discussion**

Since the development of the current immunoseparation method, many investigators have reported an association between RLP-C and RLP-TG levels and atherosclerosis, CVD, or CHD. However, in models including total cholesterol or HDL and LDL cholesterol levels, only RLPs were significant. Therefore, RLP levels provided information regarding CHD risk in addition to that provided by total cholesterol or LDL and HDL cholesterol.

In this study population, fasting triglyceride level was also an independent predictor of CHD relative risk after adjustment for age, BMI, smoking, alcohol intake, physical activity, systolic blood pressure, fasting glucose, history of diabetes, intake of antihypertensive medication, and LDL and HDL cholesterol. However, in models including an RLP variable and triglyceride level simultaneously, neither variable was predictive of CHD risk when adjusted for the other. Therefore, RLP levels did not provide additional information about risk of CHD over and above total triglyceride level. This finding can be attributed to the strong correlation between RLP-C and RLP-TG levels and total triglycerides.

In a healthy middle-aged male population, Karp et al tested log-transformed RLP variables and triglycerides as continuous variables in multiple stepwise linear regression models and found that, independently of plasma triglycerides and LDL cholesterol, the plasma concentration of fasting RLP-C is related to intima-media thickness of the carotid artery, a marker of the early development of atherosclerosis. However, when we repeated our analyses with log-transformed RLP variables and triglycerides, no evidence was found that RLP levels provide additional information about risk of CHD over and above total triglyceride level in this population.

The Adult Treatment Panel III report of the National Cholesterol Education Program recognizes elevated triglyceride level as an independent CHD risk factor. It identifies VLDL cholesterol as the most readily available measure of atherogenic remnant lipoproteins and recommends VLDL cholesterol as a target for cholesterol-lowering therapy. The Adult Treatment Panel III limits this recommendation to individuals with elevated triglycerides; it identifies the sum of LDL+VLDL cholesterol (termed “non-HDL cholesterol” [total cholesterol−HDL cholesterol]) as a secondary target of therapy in persons with elevated triglycerides (triglycerides $>200$ mg/dL). When subjects in our study with normal triglyceride levels were separated from those with elevated triglycerides, a significant association between RLP levels and relative risk of CHD was found only for the group with elevated triglycerides. However, the regression coefficients estimates were very similar. The standard errors of the regression coefficients for the group with normal triglycerides were much larger than those for the group with elevated triglyceride levels, probably attributable to the smaller variability among individual RLP levels in this group. This contributed to the nonsignificant outcome for the normal triglyceride group. Thus, it is unlikely that there is a difference in the character of the relationship between RLP levels and CHD relative risk. RLP and triglyceride levels are strongly correlated and the distributions of RLP-C and RLP-TG are highly skewed to the right. Therefore, people with elevated triglycerides are more likely to have disproportionately high levels of RLP than people with normal triglyceride levels.

In our study in models that included an RLP variable and triglyceride level simultaneously, neither variable was significant when adjusted for the other. Therefore, even when attention was restricted to men with elevated triglyceride levels, no evidence was found that RLP levels provide additional information about risk of CHD over and above total triglyceride level.

Full RLP compositional data are lacking. ApoC-III plays a major role in atherosclerosis and is a known component of remnants in the 1.006 to 1.019 density range. Apo E is thought to be protective because it enhances receptor-mediated uptake. The metabolism of human VLDL particles is influenced by their content of apoE and is modulated by apoC-III. The findings of this study point to the important role of triglyceride-rich lipoprotein particles in atherosclerosis. These triglyceride-rich particles contain apoB. Therefore, apoB-containing and probably apoC-III–containing triglyceride-rich particles may be responsible, in part, for the strong relationship of triglyceride with CHD. It should be emphasized that the triglyceride relationship with CHD suggests a wider involvement of triglyceride-rich particles in atherosclerosis than RLP-TG and that other remnant particles should also be considered in risk factor analysis.

In summary, RLP levels predicted risk of CHD independently of other nonlipid cardiovascular risk factors for CHD. Furthermore, RLP levels predicted CHD relative risk independently of total cholesterol or HDL and LDL cholesterol levels. Importantly, however, RLP levels did not provide additional information about risk of CHD over and above total triglyceride levels in this cohort. This finding can be attributed to the strong correlation between RLP-C and RLP-TG levels and total triglycerides. Therefore, this study does not support the need for testing of remnants if measures of fasting triglycerides are available and provides further evidence that triglycerides are an independent risk factor for CHD in men. However, further investigation of particular component RLPs and their relationship to cardiovascular disease appears warranted.

**Acknowledgments**

This work was supported by an American Heart Association Established Investigator Award (9940159), the Honolulu Heart Program (contract NO1-HC-05102), and the National Heart Lung and Blood Institute (U01HL56274).

**References**


Are Remnant-Like Particles Independent Predictors of Coronary Heart Disease Incidence? The Honolulu Heart Study
Claudia Imke, Beatriz L. Rodriguez, John S. Grove, Judith R. McNamara, Carol Waslien, Alan R. Katz, Bradley Willcox, Katsuhiko Yano and J. David Curb

Arterioscler Thromb Vasc Biol. published online June 9, 2005;
Arteriosclerosis, Thrombosis, and Vascular Biology is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Copyright © 2005 American Heart Association, Inc. All rights reserved.
Print ISSN: 1079-5642. Online ISSN: 1524-4636

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://atvb.ahajournals.org/content/early/2005/06/09/01.ATV.0000173310.85845.7b.citation

Permissions: Requests for permissions to reproduce figures, tables, or portions of articles originally published in Arteriosclerosis, Thrombosis, and Vascular Biology can be obtained via RightsLink, a service of the Copyright Clearance Center, not the Editorial Office. Once the online version of the published article for which permission is being requested is located, click Request Permissions in the middle column of the Web page under Services. Further information about this process is available in the Permissions and Rights Question and Answer document.

Reprints: Information about reprints can be found online at:
http://www.lww.com/reprints

Subscriptions: Information about subscribing to Arteriosclerosis, Thrombosis, and Vascular Biology is online at:
http://atvb.ahajournals.org//subscriptions/